Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 22 2022 - 8:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 21, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
| Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase
programme
Bagsværd,
Denmark, 21 March 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article
5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up
to DKK 22 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 2 February 2022, Novo Nordisk
will repurchase B shares for an amount up to DKK 4.4 billion in the period from 2 February 2022 to 2 May 2022.
Since the announcement 14 March 2022, the following transactions
have been made:
| |
Number of
B shares |
Average
purchase
price |
Transaction
value, DKK |
| Accumulated, last announcement |
3,029,151 |
|
2,044,226,993 |
| 14 March 2022 |
100,000 |
691.79 |
69,179,291 |
| 15 March 2022 |
100,000 |
691.47 |
69,147,046 |
| 16 March 2022 |
95,000 |
713.21 |
67,754,522 |
| 17 March 2022 |
100,000 |
724.66 |
72,466,457 |
| 18 March 2022 |
100,000 |
736.07 |
73,606,764 |
| Accumulated under the programme |
3,524,151 |
|
2,396,381,074 |
The details for each transaction made under the share repurchase programme
are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of
35,310,319 B shares of DKK 0.20 as treasury shares, corresponding to 1.5% of the share capital. The total amount of A and B shares
in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK
22 billion during a 12- month period beginning 2 February 2022. As of 18 March 2022, Novo Nordisk has since 2 February 2022
repurchased a total of 3,524,151 B shares at an average share price of DKK 679.99 per B share equal to a transaction value of DKK
2,396,381,074.
Novo Nordisk is a leading global healthcare company, founded in 1923
and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and
rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: |
|
|
| Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
| Michael Bachner (US) |
+1 609 664 7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Ann Søndermølle Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
| Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
| Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
| |
|
Company announcement No 24 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: March 21, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Nov 2023 to Nov 2024
